PDCD1 and glioblastoma: For example, the CheckMate-548 trial (NCT02667587) investigated the impact of incorporating nivolumab (anti-PD-1 mAb) into the established standard of care (temozolomide and radiation therapy) compared to a placebo combined with the standard care for a subset of GBM patients [89].